Malignant Glioma Clinical Trials

14 recruiting

Malignant Glioma Trials at a Glance

20 actively recruiting trials for malignant glioma are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 14 trials, with the heaviest enrollment activity in Houston, Columbus, and Boston. Lead sponsors running malignant glioma studies include Mayo Clinic, M.D. Anderson Cancer Center, and Children's Oncology Group.

Browse malignant glioma trials by phase

Treatments under study

About Malignant Glioma Clinical Trials

Looking for clinical trials for Malignant Glioma? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 1Phase 2

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Malignant Glioma
National Cancer Institute (NCI)132 enrolled127 locationsNCT05099003
Recruiting
Phase 1

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

High Grade GliomaAdult GlioblastomaWHO Grade III or IV Malignant Glioma
University of Florida28 enrolled1 locationNCT04573140
Recruiting
Phase 1

Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial

Malignant Glioma
Mayo Clinic28 enrolled2 locationsNCT05030298
Recruiting
Phase 1

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+2 more
Beijing Biotech36 enrolled1 locationNCT07551336
Recruiting
Not Applicable

Non-invasive Glioma Characterization Through Molecular Imaging

Brain TumorGliomaPrimary Brain Tumor+2 more
University of Miami30 enrolled1 locationNCT03684109
Recruiting
Phase 1

Chronic CED of TPT for Recurrent Malignant Glioma

Brain Tumor, RecurrentMalignant Glioma (WHO Grade III or IV)IDH1/IDH2 Mutation
Jeffrey N. Bruce6 enrolled1 locationNCT06666712
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979
Recruiting

Serial Advanced Magnetic Resonance Imaging Scan for Guidance of Personalized Adaptive Radiotherapy for High Grade Glioma

Malignant Glioma
M.D. Anderson Cancer Center80 enrolled1 locationNCT04771806
Recruiting
Phase 1

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent GlioblastomaRecurrent Malignant GliomaRecurrent Gliosarcoma+2 more
M.D. Anderson Cancer Center36 enrolled1 locationNCT03896568
Recruiting
Not Applicable

T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas

Malignant Glioma
John M. Buatti15 enrolled1 locationNCT07447531
Recruiting
Phase 1Phase 2

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Malignant Brain NeoplasmMalignant Glioma
Stanford University46 enrolled1 locationNCT03510208
Recruiting
Phase 1

CARv3-TEAM-E T Cells in Glioblastoma

GlioblastomaMalignant GliomaRecurrent Glioblastoma+1 more
Marcela V. Maus, M.D.,Ph.D.21 enrolled1 locationNCT05660369
Recruiting

Mapping of Electrical Properties in the Brain

Malignant Glioma
Mayo Clinic120 enrolled1 locationNCT06470711
Recruiting
Phase 1

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.

Brain TumorBrain CancerGlioblastoma+6 more
Henry Ford Health System18 enrolled1 locationNCT05686798
Recruiting
Phase 1

Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients

Malignant GliomaMalignant Brain TumorEmbryonal Tumor
Assistance Publique - Hôpitaux de Paris24 enrolled3 locationsNCT05293197
Recruiting
Early Phase 1

Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma

Diffuse GliomaMalignant Glioma
Mayo Clinic18 enrolled1 locationNCT05717153
Recruiting
Phase 1

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

Recurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 GliomaRecurrent Malignant Glioma+3 more
Ohio State University Comprehensive Cancer Center30 enrolled1 locationNCT06964737
Recruiting
Not Applicable

Fitness and Nutrition in Glioma

Malignant Glioma
NYU Langone Health15 enrolled1 locationNCT06665373
Recruiting
Phase 1

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

GlioblastomaMalignant GliomaRecurrent Glioblastoma+3 more
Sabine Mueller, MD, PhD20 enrolled20 locationsNCT04323046